Relief For UniQure Hemophilia Program Sends Ball To FTC’s Court
Good News For Gene Therapy Continues As FDA Also Removes Hold On Voyager’s Huntington’s Trial
Executive Summary
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
You may also be interested in...
UniQure Needs Longer-Term Data For Hemophilia B Gene Therapy EtranaDez
The FDA may want longer follow-up data for companies developing treatments for hemophilia A as well as hemophilia B.
Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.
Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.